You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

September 4, 2026

Surprise Inside! Thai Regulations for Food Products with Randomized Toys

Blind boxes and collectibles have become increasingly popular, driven by the excitement of not knowing which character or design will be revealed until the package is opened. While most visible in the art toy market, the same concept is also used in the food industry.

Confectionery, snacks, and other food products are sometimes sold with toys, character figures, cards, or other collectibles. A package might, for example, contain one of ten possible characters, with consumers knowing that an item is included but not which one they will receive. Some collections may also feature rare or “secret” items.

For food businesses, however, adding a randomized toy or collectible involves more than a marketing decision. The food, the nonfood item, and the randomized mechanism may each raise different regulatory considerations in Thailand.

Thai FDA Requirements for Nonfood Objects Packaged with Food

The main food regulatory consideration is Ministry of Public Health Notification No. 310 B.E. 2551 (2008), which regulates food packaged together with things or objects that are not food. Under Notification No. 310, certain nonfood objects may be packaged together with food where they fall within specified exceptions, including objects that serve the following purposes:

  • Maintaining the quality or standard of the food, such as a desiccant or oxygen absorber;
  • Serving as a seasoning or as part of food preparation, such as chili powder sachets or seasoning sachets contained in instant noodle packages; or
  • Functioning as an eating or food-preparation utensil, such as a spoon or fork included with instant noodles.

Other nonfood objects that do not fall within these categories generally should not be placed inside the food container together with the food. Where a toy, collectible, or other nonfood object is intended to be sold together with a food product, businesses should therefore carefully consider the nature of the object, how it is packaged and separated from the food, and the applicable Thai FDA requirements on a case-by-case basis.

In practice, the packaging arrangement should be assessed to ensure that the nonfood object does not create a health risk or cause consumers to mistakenly believe that it is edible. Depending on the specific packaging arrangement, this may involve placing the nonfood item outside the immediate food container, separately packaging it within the overall package, clearly separating the respective compartments, or attaching the promotional item externally to the food package.

When the Randomized Item Is a Toy

Where the nonfood item is a toy, a separate regulatory regime may also apply. Toys intended for children under 14 years of age may be subject to Thailand’s mandatory product safety requirements administered by the Thai Industrial Standards Institute (TISI), including TIS 685 on toys, depending on the characteristics and classification of the product. These requirements apply separately from the Thai FDA requirements applicable to the food and its packaging.

This is particularly relevant for imported products. A food product may need to satisfy Thai FDA requirements, while a toy included with it may separately require compliance with applicable TISI requirements.

In practice, businesses should therefore assess both the packaging arrangement under Thai FDA requirements and the toy itself under the applicable product safety requirements.

Randomized Toys, Different Values, and Other Legal Considerations

In situations where the toys are randomized, the fact that consumers do not know which toy they will receive does not, by itself, change the food regulatory analysis under Notification No. 310. Nor does the presence of randomness necessarily mean that the arrangement constitutes gambling.

However, separate legal considerations may arise depending on how the randomized mechanism is structured and marketed. One relevant factor may be the relative commercial value of the possible items. If the possible items have materially different values, the arrangement may raise different considerations than situations where the items are of broadly comparable value and the random element is primarily which character or design the consumer receives. For example, if most packages contain ordinary figures while a small number contain rare or “secret” items of substantially higher value, the difference in value may become relevant to the gambling-law analysis. Even where every consumer is guaranteed to receive an item, the element of chance may determine whether the item received is worth less than, equal to, or more than the amount paid. This may raise considerations relating to the risk of gaining or losing value under Thailand’s Gambling Act B.E. 2478 (1935), as the nature and value of the possible items, whether any additional prize or premium is offered by chance, and the overall structure of the promotion may also be relevant.

A related issue may arise where additional prizes or premiums are randomly included with the purchased product. Depending on the structure, this may fall within the provisions of the Gambling Act concerning the offering of premiums or prizes by chance, for which prior permission may be required.

The treatment of claw machines provides a useful comparison. Under the Gambling Act, as amended, certain amusement machines capable of producing a win-or-lose outcome may fall within the gambling regulatory framework. In a conventional claw-machine arrangement, a player pays for each attempt but may receive nothing if unsuccessful. The outcome therefore determines whether the player receives an item at all.

When assessing the regulatory implications of randomized items, the analysis should consider the overall structure of the transaction, including whether the consumer is guaranteed to receive an item, the relative value of the possible items, the role of chance in determining the outcome, and how the promotion is structured and marketed. Whether a particular arrangement raises issues under the Gambling Act will ultimately depend on its specific circumstances and should be assessed separately on a case-by-case basis.

One Product, Multiple Regulatory Considerations

A food product containing a randomized toy may appear to consumers as a single product, but businesses may need to consider several regulatory layers: Thai FDA requirements for the food and the packaging of a nonfood object with it, TISI safety and compliance requirements applicable to the toy, and other applicable laws that may be relevant to the structure of any randomized or chance-based promotional mechanism.

Each regime addresses a different regulatory issue. Compliance with Thai FDA requirements, for example, has no bearing on whether the toy complies with TISI requirements or whether the promotional mechanism raises issues under other laws.

Key Takeaways for Food Businesses

As food brands increasingly use collectibles, character collaborations, and blind-box-style concepts, these regulatory considerations should be addressed early in product development.

For food products containing randomized toys, businesses should consider what the nonfood item is, how it is packaged with and separated from the food, whether separate product standards apply to the toy, and how any randomized mechanism is structured and promoted.

Where the possible collectibles have materially different relative commercial values, additional legal review may also be appropriate, particularly where the promotion emphasizes the chance of obtaining a rare or high-value item.

Ultimately, what appears to consumers as a simple “surprise inside” may involve several regulatory layers. Identifying these considerations early in product development can help food businesses address potential regulatory issues before the product reaches the Thai market.

RELATED INSIGHTS​ 

August 29, 2023
Laos’ Ministry of Health (MOH) has promulgated a regulation detailing registration and notification protocols for medical devices. Decision on the Registration and Notification of Medical Devices No. 1470/MOH will come into force 60 days after both the signing of the regulation (which already occurred in July) and publication in the Official Gazette, which has not yet been specified by the government. Registration of medical devices in Laos is mentioned in the country’s Law on Drugs and Medical Products No. 07/NA, dated December 21, 2011, but a registration procedure has not been put in place. There was only a separate requirement to furnish certain required documents when importing medical devices. Now, the decision outlines the registration and notification process for medical devices through the Ministry of Health’s Food and Drug Department (FDD), in line with the regulatory principles in the ASEAN Medical Device Directive of 2015, which Laos has ratified. Medical Devices in Laos The decision defines medical devices as any instrument, apparatus, implement, machine, appliance, implant, in vitro reagent or calibrator, software, material, or other similar or related article intended for any of the following uses in humans: Diagnosis, prevention, monitoring, recovery from, or alleviation or treatment of a disease; Diagnosis, monitoring, recovery from, or alleviation of or compensation for an injury; Replacement, modification, or support of anatomy or a physiological process; Supporting and sustaining life; Controlling or assisting in conception; or Disinfection and sterilization of tools and medical devices. Medical devices in Laos are given one of four classifications based on their level of risk: Class A – Low risk (e.g., rubber belts, cotton for medical purposes, nonwoven swabs, adhesive bandages) Class B – Low-moderate risk (e.g., neonatal suction equipment, surgical gloves, gastro-catheters) Class C – Moderate-high risk (e.g., endoscopic surgical equipment, anesthesia equipment, peritoneal dialysis equipment) Class
August 29, 2023
Since the June 9, 2022, delisting of all parts of the cannabis plant according to the Narcotics Code, there has been an explosion of cannabis dispensaries operating in Thailand. The Department of Thai Traditional and Alternative Medicine (DTTAM) has issued more than 12,000 cannabis dispensary licenses to businesses in Thailand. A license allows a dispensary to sell cannabis flowers legally. In addition, the DTTAM requests the cooperation of dispensaries in submitting monthly reports about the sourcing, selling, and inventory of cannabis flowers. The DTTAM may suspend the selling license of dispensaries that fail to submit these reports. Apart from the enforcement duties and administrative acts of the DTTAM, the enactment of the laws and regulations pertaining to cannabis seemed to be drastically winding down. One of the reasons was that Thailand had delays in the process of forming a new government following the general election of May 14, 2023. These delays dampened Thailand’s thriving cannabis industry. In particular, the industry has concerns about the uncertainty of the nascent cannabis law. On August 11, 2023, the Narcotics Control Division of the Thai Food and Drug Administration (FDA) posted the Draft Regulation Re: Application for Approval and Approval for Manufacture, Importation, Exportation, Distribution or Possession of Narcotics under Category 5 (Extracts from Cannabis or Hemp Plants Only). This may be the first regulation that the newly formed government implements with regard to cannabis extracts. Unlike the DTTAM’s enforcement activities, the Thai FDA requests that a domestic manufacturer, importer, exporter, or seller of cannabis extracts apply for a license. The Thai FDA, as the authority, will consider granting a license only in the following cases: For medical benefits; For commercial or industrial benefits; For the benefit of medical or scientific analysis or research; and For use by the government for preventing and
July 11, 2023
Enacted in 2009, Indonesia’s current Law on Health (Law No. 36/2009) is due for a refresh. The government realized that the law has not maintained its relevance when it comes to health trends such as digital health, which refers to the provision of health services online (also commonly known as telemedicine). While regulations and policy blueprints, such as Ministry of Health (MOH) Regulation No. 46/2017 concerning National E-Health Strategies, have addressed these shifting trends, Indonesia’s main health legislation has proved inadequate in this regard. For this reason, the government began making plans for an update to the law, and the first draft Omnibus Health Law was published in March 2023. The law addresses digital health and other important issues in today’s health landscape, and it seeks to promote the use of locally made health supplies. The draft Omnibus Health Law represents a notable step forward, but in its attempt to govern and regulate all aspects of health, there are also some issues in the draft that may overlap with some existing government regulations, such as provisions on Halal certification, compulsory licensing of patents, and addictive substances. This article outlines some of the draft law’s key aspects as well as some potential issues. Digital Health In addressing the growing health trend of telemedicine, the draft law confirms, reinforces, and fills gaps left by Indonesia’s three main regulations concerning telemedicine. namely, MOHR No. 20/2019 concerning Telemedicine, MOHR No. 24/2022 concerning Medical Records, and Medical Council Regulation No. 74/2020 concerning Telemedicine (MCR No. 74/2020). One of these regulations, MOH Regulation No. 20/2019, allows health service facilities to provide telemedicine services to other health service facilities. This covers telemedicine services related to radiology, electrocardiography, ultrasonography, and telemedicine consultancy services—including those that reflect developments in science and technology. This is the only regulation concerning
July 10, 2023
One of the more positive outcomes of the COVID-19 pandemic is that telemedicine has become remarkably important as an interactive system between patients and healthcare professionals. Thailand, which ranks near the top as a world medical hub, is a highly favored destination in Asia for expat workers. Currently, the Thai market has both Thai-based and foreign-based platforms with information about healthcare providers and telemedicine readily available. “Doctor Locator,” “Weed Map,” and “Find a Teeth Aligner Dentist” are examples of online platforms connecting patients with medical and telemedicine services. These digital platforms provide information about the location of specialized clinics, cannabis dispensaries, pharmacy stores, and orthodontic practitioners in Thailand. These platforms act as intermediaries between medical care businesses and consumers. As actual medical services are not offered or provided, these digital platforms do not have to be regulated under the Medical Facility Act of Thailand. However, healthcare digital platform services that act as an intermediary or conduit managing information used to connect medical clinics or cannabis dispensaries with patients or customers via a computer network are now regulated under the soon-to-be-implemented Royal Decree on Digital Platforms, regardless of whether payment is actually made via the platform. The regulatory authority for this is the Electronic Transactions Development Agency (ETDA). Under this royal decree, digital platform providers that intend to operate a digital platform service must notify the ETDA prior to initiating operations. The extent of the details to be included in the notification to the ETDA will be more comprehensive if the digital platform: has annual revenue (before expenses) for digital platform services within Thailand exceeding THB 1.8 million (approx. USD 51,200) for an individual operator or THB 50 million (approx. USD 1.42 million) for a corporate or entity operator; or has more than 5,000 users (on average) per month. Apart